| Pharmaceutical Information |
| Drug Name |
Ibritumomab tiuxetan |
| Drug ID |
BADD_D01118 |
| Description |
Indium or yttrium conjugated murine IgG1 kappa monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B lymphocytes. Ibritumomab is produced in Chinese hamster ovary cells and is composed of two murine gamma 1 heavy chains of 445 amino acids each and two kappa light chains of 213 amino acids each. |
| Indications and Usage |
For treatment of non-Hodgkin's lymphoma |
| Marketing Status |
approved; investigational |
| ATC Code |
Not Available |
| DrugBank ID |
DB00078
|
| KEGG ID |
D04489
|
| MeSH ID |
C422802
|
| PubChem ID |
92002593
|
| TTD Drug ID |
Not Available
|
| NDC Product Code |
72893-007 |
| UNII |
4Q52C550XK
|
| Synonyms |
ibritumomab tiuxetan | Zevalin | yttrium-90-ibritumomab tiuxetan | IDEC-Y2B8 | IDEC-Y2B8 IDEC-129 | IDEC-129 |
|
| Chemical Information |
| Molecular Formula |
C24H35N5O11 |
| CAS Registry Number |
206181-63-7 |
| SMILES |
CC(CN(CC(CC1=CC=C(C=C1)NC(=O)NC)N(CC(=O)O)CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
